Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.44 |
| ▸ | VNN1 | O95497 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | AURKA | O14965 | 2/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.39 |
| ▸ | RET | P07949 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14801448 | 0.91 | CA1 (0.49) | ALDH1A1AURKAHDAC1POLBCA1 | |
| SCHEMBL17797436 | 0.90 | VNN1 (0.44) | VNN1NPC1RAB9AP2RX3ALDH1A1 | |
| SCHEMBL16012065 | 0.85 | VNN1 (0.44) | DRD2TBXA2RVNN1NPC1RAB9A | |
| SCHEMBL16011866 | 0.83 | VNN1 (0.42) | DRD2TBXA2RVNN1NPC1RAB9A | |
| SCHEMBL16023882 | 0.83 | DRD2 (0.43) | DRD2TBXA2RVNN1NPC1RAB9A | |
| SCHEMBL19221575 | 0.83 | DRD2 (0.43) | DRD2TBXA2RVNN1NPC1RAB9A | |
| SCHEMBL22084214 | 0.82 | VNN1 (0.57) | DRD2TBXA2RVNN1NPC1RAB9A | |
| SCHEMBL14802065 | 0.81 | PTGS2 (0.45) | VNN1CA1CA2 | |
| SCHEMBL16211422 | 0.78 | RAB9A (0.54) | DRD2TBXA2RVNN1NPC1RAB9A | |
| SCHEMBL16012001 | 0.77 | JAK2 (0.45) | VNN1RAB9AP2RX3ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2964630-B9 | PYRIMIDINE COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL MYERS SQUIBB CO (US) | 2017-08-09 | — | — | EP | disclosed |
| EP-2964630-B9 | PYRIMIDINE COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL MYERS SQUIBB CO (US) | 2017-08-09 | — | — | EP | disclosed |
| US-9656992-B2 | Pyrimidine compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-05-23 | — | — | US | disclosed |
| US-9656992-B2 | Pyrimidine compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-05-23 | — | — | US | disclosed |
| US-9656992-B2 | Pyrimidine compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-05-23 | — | — | US | disclosed |
| EP-2964630-B1 | PYRIMIDINE COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL MYERS SQUIBB CO (US) | 2017-05-10 | — | — | EP | disclosed |
| EP-2964630-B1 | PYRIMIDINE COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL MYERS SQUIBB CO (US) | 2017-05-10 | — | — | EP | disclosed |
| US-20160159769-A1 | Pyrimidine Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-06-09 | — | — | US | disclosed |
| US-20160159769-A1 | Pyrimidine Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-06-09 | — | — | US | disclosed |
| US-20160159769-A1 | Pyrimidine Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-06-09 | — | — | US | disclosed |
| EP-2964630-A1 | PYRIMIDINE COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | Bristol-Myers Squibb Company (US) | 2016-01-13 | — | — | EP | disclosed |
| WO-2014138199-A1 | PYRIMIDINE COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-12 | — | — | WO | disclosed |
| WO-2014138199-A1 | PYRIMIDINE COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160159769-A1 | Pyrimidine Compounds for the Treatment of Hepatitis C | TYMP, UMPS, NUDT1 | DRD2 4201/4885TBXA2R 772/4885VNN1 1579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.